Abstract: Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of diseases and conditions associated with expression of diacylglycerol acyltransferase 2 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of p70 S6 kinase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding p70 S6 kinase. Methods of using these compounds for modulation of p70 S6 kinase expression and for treatment of diseases associated with expression of p70 S6 kinase are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of Aurora B. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Aurora B. Methods of using these compounds for modulation of Aurora B expression and for diagnosis and treatment of diseases and conditions associated with expression of Aurora B are provided. Also provided are methods of using these compounds to modulate the growth of cancer cells, including p53-deficient cancer cells.

Abstract: Compounds, compositions and methods are provided for modulating the expression of Nanos 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Nanos 1. Methods of using these compounds for modulation of Nanos 1 expression and for diagnosis and treatment of diseases and conditions associated with expression of Nanos 1 are provided.

Abstract: Compositions and methods are provided for decreasing blood glucose levels in an animal, comprising administering to said animal an antisense inhibitor of glucose-6-phosphatase translocase expression alone or in combination with at least one glucose-lowering drug. Also provided are compositions and methods for treating diabetes and other metabolic disorders.

Abstract: Compounds, compositions and methods are provided for modulating the expression of Pumilio 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Pumilio 1. Methods of using these compounds for modulation of Pumilio 1 expression and for diagnosis and treatment of diseases and conditions associated with expression of Pumilio 1 are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of STAT 6. The compositions comprise oligonucleotides, targeted to nucleic acid encoding STAT 6. Methods of using these compounds for modulation of STAT 6 expression and for diagnosis and treatment of disease associated with expression of STAT 6 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of TFAP2C. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding TFAP2C. Methods of using these compounds for modulation of TFAP2C expression and for treatment of diseases associated with expression of TFAP2C are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of kallikrein 6. The compositions comprise oligonucleotides, targeted to nucleic acid encoding kallikrein 6. Methods of using these compounds for modulation of kallikrein 6 expression and for diagnosis and treatment of disease associated with expression of kallikrein 6 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of mucin 1, transmembrane. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding mucin 1, transmembrane. Methods of using these compounds for modulation of mucin 1, transmembrane expression and for treatment of diseases associated with expression of mucin 1, transmembrane are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of thyroid hormone receptor interactor 6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding thyroid hormone receptor interactor 6. Methods of using these compounds for modulation of thyroid hormone receptor interactor 6 expression and for treatment of diseases associated with expression of thyroid hormone receptor interactor 6 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of sterol regulatory element-binding protein-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding sterol regulatory element-binding protein-1. Methods of using these compounds for modulation of sterol regulatory element-binding protein-1 expression and for treatment of diseases associated with expression of sterol regulatory element-binding protein-1 are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of tyrosinase. The compositions comprise oligonucleotides, targeted to nucleic acid encoding tyrosinase.

Abstract: Compounds, compositions and methods are provided for modulating the expression of Notch2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Notch2. Methods of using these compounds for modulation of Notch2 expression and for diagnosis and treatment of diseases and conditions associated with expression of Notch2 are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of ACE2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding ACE2. Methods of using these compounds for modulation of ACE2 expression and for diagnosis and treatment of diseases and conditions associated with expression of ACE2 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of dual specific phosphatase 5. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding dual specific phosphatase 5. Methods of using these compounds for modulation of dual specific phosphatase 5 expression and for treatment of diseases associated with expression of dual specific phosphatase 5 are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of eIF4E-BP2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding eIF4E-BP2. Methods of using these compounds for modulation of eIF4E-BP2 expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E-BP2 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of G protein-coupled receptor kinase 6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G protein-coupled receptor kinase 6. Methods of using these compounds for modulation of G protein-coupled receptor kinase 6 expression and for treatment of diseases associated with expression of G protein-coupled receptor kinase 6 are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of DC-SIGN. The compositions comprise oligonucleotides, targeted to nucleic acid encoding DC-SIGN. Methods of using these compounds for modulation of DC-SIGN expression and for diagnosis and treatment of diseases and conditions associated with expression of DC-SIGN are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of eIF4E-BP1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding eIF4E-BP1. Methods of using these compounds for modulation of eIF4E-BP1 expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E-BP1 are provided.